---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035262"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:06:49.377023+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive

## Summary
- Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.
- Adjusted earnings $0.2M ($0.01/share), a $0.8M improvement vs prior Q1 period.
- Net loss $1.1M ($0.08/share) in Q2; year-to-date net loss $3.0M ($0.21/share).
- Product revenue: Kristalose $4.1M, Vibativ $2.5M, Sancuso $2.2M, Caldolor $0.8M in Q2.
- Cash $17.3M; $16.1M drawn on credit line; total assets $78.5M.

## SEC filing metadata
- accession: 0001628280-24-035262
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828024035262/0001628280-24-035262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828024035262/cpix-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035262
- JSON: https://secwatch.observer/filing/0001628280-24-035262.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.